Papers [Regulatives / Guidelines]

posted by Mahmoud  – Jordan, 2021-09-17 15:31 (940 d 22:20 ago) – Posting: # 22580
Views: 2,514

Dear all

Dr Anders Fuglsang discussed in his paper

Mitigation of the convergence issues associated with semi-replicated bioequivalence data. Pharmaceutical Statistics. 2021;1–3
used the proc mixed in RTR/TRR/RRT design in ABE

I think that using proc mixed to fit RTR/TRR/RRT design is not suitable, because in most cases proc mixed produced Estimated G matrix is not positive definite.

So proc GLM recommended by FDA and Emea is more appropriate in the Semi-replicated designs

M.Youseef


Edit: Post moved. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,983 posts in 4,822 threads, 1,648 registered users;
32 visitors (0 registered, 32 guests [including 4 identified bots]).
Forum time: 13:52 CEST (Europe/Vienna)

Complex, statistically improbable things are by their nature
more difficult to explain than
simple, statistically probable things.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5